A Luciferase Based Viability Assay for ATP Detection in 384-well Format for High Throughput Whole Cell Screening of Trypanosoma Brucei Brucei Bloodstream Form Strain 427

Overview

Journal Parasit Vectors

Publisher Biomed Central

Specialties Parasitology
Tropical Medicine

Date 2009 Nov 14

PMID 19909542

Citations 15

Authors

Melissa L Sykes

Vicky M Avery

Affiliations

Soon will be listed here.

Abstract

Background: Human African Trypanosomiasis (HAT) is caused by two trypanosome species, Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Current drugs available for the treatment of HAT have significant issues related to toxicity, administration regimes with limited effectiveness across species and disease stages, thus there is a considerable need to find alternative drugs. A well recognised approach to identify new drug candidates is high throughput screening (HTS) of large compound library collections.

Results: We describe here the development of a luciferase based viability assay in 384-well plate format suitable for HTS of T.b.brucei. The parameters that were explored to determine the final HTS assay conditions are described in detail and include DMSO tolerability, Z', diluents and cell inoculum density. Reference compound activities were determined for diminazene, staurosporine and pentamidine and compared to previously published IC50 data obtained. The assay has a comparable sensitivity to reference drugs and is more cost effective than the 96-well format currently reported for T.b.brucei.

Conclusion: Due to the reproducibility and sensitivity of this assay it is recommended for potential HTS application. As it is commercially available this assay can also be utilised in many laboratories for both large and small scale screening.

Citing Articles

Past and future of trypanosomatids high-throughput phenotypic screening.

Dantas R, Torres-Santos E, Silva Jr F Mem Inst Oswaldo Cruz. 2022; 117:e210402.

PMID: 35293482 PMC: 8920514. DOI: 10.1590/0074-02760210402.

Sensitive quantification of α-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid.

Nitschke S, Petkovic S, Ahonen S, Minassian B, Nitschke F J Biol Chem. 2020; 295(43):14698-14709.

PMID: 32817315 PMC: 7586225. DOI: 10.1074/jbc.RA120.015061.

Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Bhattacharya A, Corbeil A, do Monte-Neto R, Fernandez-Prada C Genes (Basel). 2020; 11(7).

PMID: 32610603 PMC: 7397081. DOI: 10.3390/genes11070722.

The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against Acanthamoeba castellanii.

Shing B, Singh S, Podust L, McKerrow J, Debnath A Antimicrob Agents Chemother. 2020; 64(5).

PMID: 32094126 PMC: 7179639. DOI: 10.1128/AAC.02223-19.

Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.

Berry S, Hameed H, Thomason A, Maciej-Hulme M, Abou-Akkada S, Horrocks P PLoS Negl Trop Dis. 2018; 12(7):e0006639.

PMID: 30001317 PMC: 6057649. DOI: 10.1371/journal.pntd.0006639.

References

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

Bales Jr J, Harrison S, Mbwabi D, Schecter P . Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 1989; 83 Suppl 1:111-4. DOI: 10.1080/00034983.1989.11812414. View

Mpia B, Pepin J . Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop Med Int Health. 2002; 7(9):775-9. DOI: 10.1046/j.1365-3156.2002.00933.x. View

Gulden M, Morchel S, Seibert H . Serum albumin binding at cytotoxic concentrations of chemicals as determined with a cell proliferation assay. Toxicol Lett. 2003; 137(3):159-68. DOI: 10.1016/s0378-4274(02)00399-5. View

Iversen P, Eastwood B, Sittampalam G, Cox K . A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. J Biomol Screen. 2006; 11(3):247-52. DOI: 10.1177/1087057105285610. View

Martyn D, Jones D, Fairlamb A, Clardy J . High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorg Med Chem Lett. 2007; 17(5):1280-3. PMC: 3428910. DOI: 10.1016/j.bmcl.2006.12.016. View

Matovu E, Stewart M, Geiser F, Brun R, Maser P, Wallace L . Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell. 2003; 2(5):1003-8. PMC: 219364. DOI: 10.1128/EC.2.5.1003-1008.2003. View

Raz B, Iten M, Kaminsky R, Brun R . The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 1997; 68(2):139-47. DOI: 10.1016/s0001-706x(97)00079-x. View

Mackey Z, OBrien T, Greenbaum D, Blank R, McKerrow J . A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem. 2004; 279(46):48426-33. DOI: 10.1074/jbc.M402470200. View

10.

Sui Y, Wu Z . Alternative statistical parameter for high-throughput screening assay quality assessment. J Biomol Screen. 2007; 12(2):229-34. DOI: 10.1177/1087057106296498. View

11.

Vlodavsky I, Inbar M, Sachs L . Membrane changes and adenosine triphosphate content in normal and malignant transformed cells. Proc Natl Acad Sci U S A. 1973; 70(6):1780-4. PMC: 433595. DOI: 10.1073/pnas.70.6.1780. View

12.

Vassella E, Reuner B, Yutzy B, Boshart M . Differentiation of African trypanosomes is controlled by a density sensing mechanism which signals cell cycle arrest via the cAMP pathway. J Cell Sci. 1998; 110 ( Pt 21):2661-71. DOI: 10.1242/jcs.110.21.2661. View

13.

Sykes M, Avery V . Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am J Trop Med Hyg. 2009; 81(4):665-74. DOI: 10.4269/ajtmh.2009.09-0015. View

14.

Kinabo L . Pharmacology of existing drugs for animal trypanosomiasis. Acta Trop. 1993; 54(3-4):169-83. DOI: 10.1016/0001-706x(93)90091-o. View

15.

Hirumi H, Hirumi K . Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol. 1989; 75(6):985-9. View

16.

Braga M, De Souza W . Effects of protein kinase and phosphatidylinositol-3 kinase inhibitors on growth and ultrastructure of Trypanosoma cruzi. FEMS Microbiol Lett. 2006; 256(2):209-16. DOI: 10.1111/j.1574-6968.2006.00125.x. View

17.

Merschjohann K, Steverding D . In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolense by iron chelators. Kinetoplastid Biol Dis. 2006; 5:3. PMC: 1563472. DOI: 10.1186/1475-9292-5-3. View

18.

Arnoult D, Akarid K, Grodet A, Petit P, Estaquier J, Ameisen J . On the evolution of programmed cell death: apoptosis of the unicellular eukaryote Leishmania major involves cysteine proteinase activation and mitochondrion permeabilization. Cell Death Differ. 2002; 9(1):65-81. DOI: 10.1038/sj.cdd.4400951. View

19.

Rifkin M . Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc Natl Acad Sci U S A. 1978; 75(7):3450-4. PMC: 392795. DOI: 10.1073/pnas.75.7.3450. View

20.

Fiorani M, Cantoni O, Piccoli G, Biagiarelli B, Stocchi V . Cell density-dependent regulation of ATP levels during the growth cycle of cultured Chinese hamster ovary cells. Biochem Mol Biol Int. 1994; 32(2):251-8. View